TP53 and neoplasm: Although a careful clinical investigation is necessary to compare the therapeutic efficacy of LR‐targeting drugs between P53 WT and mutant CRC patients, our data suggest that miltefosine can target CSCs and bulk tumour cells independently of P53 status and thus has promising potential for treating a broad range of CRC patients.